Abstract
The present analytical study aims to develop and validate the RP-HPLC method for dissolution of Azelnidipine (AZE) and Telmisartan (TEL) in fixed-dose combination tablets (8 mg/40 mg) and also to demonstrate that the test method used, is suitable for its intended purpose as per ICH guidelines. The protocol developed utilizes Inertsil ODS 3V, C18 column 150 x 4.6 mm, 5 µm particle sizes, column oven temperature 40°C with a flow rate of 1.5 mL/min. The volume of injection was kept at 10 µL and run time 11.0 minutes at 254 nm using Acetonitrile and buffer as mobile phase in gradient mode. Thus developed method after validating on different parameters was found to be complying with system suitability, specificity, precision, intermediate precision, accuracy, linearity, robustness, and solution stability found to meet the predetermined acceptance criteria.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
